Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Heghine Khachatryan: Willebrand Disease – Similar Bleeding Phenotype, Distinct Pathophysiology
Heghine Khachatryan/LinkedIn
Jun 26, 2026, 15:51

Heghine Khachatryan: Willebrand Disease – Similar Bleeding Phenotype, Distinct Pathophysiology

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Glanzmann’s Research Foundation’s post on LinkedIn, adding:

“Willebrand Disease: Similar Bleeding Phenotype, Distinct Pathophysiology

Glanzmann thrombasthenia (GT) and Type 2 von Willebrand disease (VWD) may present with remarkably similar mucocutaneous bleeding symptoms—including

recurrent epistaxis, gingival bleeding, easy bruising, and heavy menstrual bleeding—making the differential diagnosis clinically challenging.

However, these disorders arise from fundamentally different defects in primary hemostasis.

Glanzmann thrombasthenia is an inherited platelet function disorder caused by qualitative or quantitative defects of the platelet integrin αIIbβ3 (GPIIb/IIIa), resulting in

severely impaired platelet aggregation despite a normal platelet count.

In contrast, Type 2 von Willebrand disease is characterized by qualitative abnormalities of von Willebrand factor that disrupt platelet adhesion and/or factor VIII stabilization, depending on the subtype.

Because clinical manifestations frequently overlap, diagnosis should never rely solely on bleeding symptoms.

Comprehensive laboratory evaluation—including platelet aggregation studies, flow cytometric assessment of platelet glycoproteins, von Willebrand factor antigen and activity assays,

multimer analysis, and targeted molecular testing when indicated—is essential for establishing the correct diagnosis and guiding appropriate therapy.

Accurate distinction between these rare bleeding disorders is critical, as therapeutic strategies differ substantially.

Misclassification may lead to ineffective treatment, avoidable bleeding complications, or unnecessary transfusion exposure.

Precision diagnosis remains the cornerstone of personalized hemostatic care.”

Glanzmann’s Research Foundation shared a post on LinkedIn about a recent article by Navin Raj Ramamurthy et al. published in Cureus, adding:

“Glanzmann Thrombasthenia and Type 2 Von Willebrand Disease often share similar symptoms, including nosebleeds, gum bleeding, and heavy menstrual bleeding,

making an accurate diagnosis difficult without specialized testing.

A recent case report highlights the critical role of platelet function studies and von Willebrand testing in distinguishing these disorders and ensuring patients receive the most appropriate treatment.”

Title: Platelet Function Disorders: Glanzmann Thrombasthenia and Type 2 Von Willebrand Disease

Authors: Navin Raj Ramamurthy, Shashank M., Sugil E., Selvakumar Selvaraj, Namitha Narayanan, Ashokraj Selvam, Dhivyapriya S.

Heghine Khachatryan: Willebrand Disease - Similar Bleeding Phenotype, Distinct Pathophysiology

Stay updated on all scientific advances with Hemostasis Today.

 

Ashokraj Selvam Dhivyapriya S. Glanzmann thrombasthenia Glanzmann's Research Foundation Health Heghine Khachatryan Hematology Hemostasis Hemostasis News Hemostasis Today Namitha Narayanan Navin Raj Ramamurthy Selvakumar Selvaraj Shashank M. Sugil E. type 2 von Willebrand disease
NewsFeed